

Letter to the Editor Concerning “Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors” [Letter]

Honglian Huang*

Tao Huang*

Renjie Wei

Hechi People's Hospital, Hechi City,
Guangxi Zhuang Autonomous Region,
People's Republic of China

*These authors contributed equally to
this work

Dear editor

We read this study¹ with great interest. At present, due to the lack of screening and diagnosis methods for ovarian cancer, there is still a lack of early diagnosis of ovarian cancer. This study uses the systemic inflammatory response index (SIRI) and platelet–lymphocyte ratio (PLR) scoring standards, by adding some different auxiliary diagnostic indicators, to improve the sensitivity of detection, which is helpful for the early detection of ovarian cancer. It is a good supplement to ovarian screening. Screening tools are necessary for early-stage diseases and must be highly specific. In view of the low absolute incidence of ovarian cancer, high specificity can avoid unnecessary intervention in false-positive cases. So far, ovarian cancer screening strategies are based on tumor biomarkers (CA125) combined with transvaginal ultrasound, which has also prompted the shift from treatment to early tumor diagnosis. However, there may be two shortcomings in this study:

1. This study lacks a comparison with the normal population. This study is based on a screening method. It may be more convincing to increase the study group of a control group of the normal population for early diagnosis comparison. This part of data may be lacking for the screening test confirmation.
2. There is no detailed distinction between the different types of ovarian cancer patients, because the expression of tumor markers in each tumor may be different. For example, someone reported in the literature,² CA 125 is positive in more than 80% of nonmucinous epithelial ovarian carcinomas and expressed in most Müllerian origin carcinomas, including fallopian tube and primary serous peritoneal carcinoma. The lacking stratification of ovarian cancer may be misleading in the application of this study.

Nevertheless, this is a novel study to introduce a scoring system to the evaluation of ovarian cancer. The results are also applauding. Thanks again for the authors' pivotal idea and research.

Correspondence: Renjie Wei
Hechi People's Hospital, No. 455 Jincheng
Middle Road, Jinchengjiang District, Hechi
City, Guangxi Zhuang Autonomous
Region, 547000, People's Republic of
China
Tel/Fax +86 778-2281409
Email wei77889908@163.com

Disclosure

The authors report no conflicts of interest for this communication.

2. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. *Cancers (Basel)*. 2020;12(12):3730. doi:10.3390/cancers12123730

References

1. Huang H, Wu K, Chen L, Lin X. Study on the application of systemic inflammation response index and platelet-lymphocyte ratio in ovarian malignant tumors. *Int J Gen Med*. 2021;14:10015–10022. doi:10.2147/IJGM.S346610

Dove Medical Press encourages responsible, free and frank academic debate. The content of the International Journal of General Medicine 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the International Journal of General Medicine editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>

<https://doi.org/10.2147/IJGM.S354920>